Santen Pharmaceutical Co Ltd 2025 SR
The report for Santen Pharmaceutical Co., Ltd. for the fiscal year 2024 highlights the company's commitment to "Happiness with Vision" and its core principle "Tenki ni sanyo suru." Key achievements include a 16.6% reduction in Scope 3 Category 1 emissions compared to the 2019 base year and achieving a 99.6% recycling rate. The company also focused on expanding access to ophthalmic care through programs like the ACT Pack for glaucoma and partnerships for nurse training in Southeast Asia. Additionally, Santen reinforced its governance by maintaining a board with 50% outside directors and 33.3% women.
Company: Santen Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2025
Type: SR
Pages: 109
Santen Pharmaceutical Co Ltd
Sustainability Report
The report for Santen Pharmaceutical Co., Ltd. for the fiscal year 2024 highlights the company's commitment to "Happiness with Vision" and its core principle "Tenki ni sanyo suru." Key achievements include a 16.6% reduction in Scope 3 Category 1 emissions compared to the 2019 base year and achieving a 99.6% recycling rate. The company also focused on expanding access to ophthalmic care through programs like the ACT Pack for glaucoma and partnerships for nurse training in Southeast Asia. Additionally, Santen reinforced its governance by maintaining a board with 50% outside directors and 33.3% women.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees